Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Sell
47
KSI.TO Quote, Financials, Valuation and Earnings
Last price:
$4.96
Seasonality move
:
13.95%
Day range:
$4.92 - $5.05
52-week range:
$4.01 - $7.25
Dividend yield:
0%
P/E ratio:
796.30x
P/S ratio:
7.89x
P/B ratio:
7.14x
Volume:
79.6K
Avg. volume:
118.1K
1-year change:
-16.92%
Market cap:
$472.9M
Revenue:
$48.9M
EPS (TTM):
-$0.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KSI.TO
kneat.com, Inc.
|
$17.1M | -$0.03 | 25.49% | -14.5% | $6.80 |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KSI.TO
kneat.com, Inc.
|
$4.96 | $6.80 | $472.9M | 796.30x | $0.00 | 0% | 7.89x |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
$0.05 | -- | $9.7M | -- | $0.00 | 0% | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
$0.0200 | -- | $205.5K | 0.52x | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KSI.TO
kneat.com, Inc.
|
31.17% | 0.549 | 5.32% | 1.58x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
40.99% | -3.518 | 19.05% | 2.85x |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-3.43% | 1.456 | 20.53% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KSI.TO
kneat.com, Inc.
|
$8.9M | -$2.1M | -1.34% | -2.02% | -13.05% | -$6.1M |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -$1.1M | -1117.27% | -- | -- | -$408.2K |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -$72.1K | -- | -- | -- | -$92.1K |
kneat.com, Inc. vs. Competitors
-
Which has Higher Returns KSI.TO or COOL.CX?
Core One Labs, Inc. has a net margin of -3.07% compared to kneat.com, Inc.'s net margin of --. kneat.com, Inc.'s return on equity of -2.02% beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KSI.TOkneat.com, Inc.55.39% -$0.01 $96.2M COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About KSI.TO or COOL.CX?
kneat.com, Inc. has a consensus price target of $6.80, signalling upside risk potential of 37.1%. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that kneat.com, Inc. has higher upside potential than Core One Labs, Inc., analysts believe kneat.com, Inc. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KSI.TOkneat.com, Inc.2 0 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is KSI.TO or COOL.CX More Risky?
kneat.com, Inc. has a beta of 1.459, which suggesting that the stock is 45.948% more volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock KSI.TO or COOL.CX?
kneat.com, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. kneat.com, Inc. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KSI.TO or COOL.CX?
kneat.com, Inc. quarterly revenues are $16.1M, which are larger than Core One Labs, Inc. quarterly revenues of --. kneat.com, Inc.'s net income of -$495.2K is higher than Core One Labs, Inc.'s net income of --. Notably, kneat.com, Inc.'s price-to-earnings ratio is 796.30x while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for kneat.com, Inc. is 7.89x versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KSI.TOkneat.com, Inc.7.89x 796.30x $16.1M -$495.2K COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns KSI.TO or CURE.X.CX?
Biocure Technology has a net margin of -3.07% compared to kneat.com, Inc.'s net margin of --. kneat.com, Inc.'s return on equity of -2.02% beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KSI.TOkneat.com, Inc.55.39% -$0.01 $96.2M CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About KSI.TO or CURE.X.CX?
kneat.com, Inc. has a consensus price target of $6.80, signalling upside risk potential of 37.1%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that kneat.com, Inc. has higher upside potential than Biocure Technology, analysts believe kneat.com, Inc. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings KSI.TOkneat.com, Inc.2 0 0 CURE.X.CXBiocure Technology0 0 0 -
Is KSI.TO or CURE.X.CX More Risky?
kneat.com, Inc. has a beta of 1.459, which suggesting that the stock is 45.948% more volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock KSI.TO or CURE.X.CX?
kneat.com, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. kneat.com, Inc. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KSI.TO or CURE.X.CX?
kneat.com, Inc. quarterly revenues are $16.1M, which are larger than Biocure Technology quarterly revenues of --. kneat.com, Inc.'s net income of -$495.2K is higher than Biocure Technology's net income of --. Notably, kneat.com, Inc.'s price-to-earnings ratio is 796.30x while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for kneat.com, Inc. is 7.89x versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KSI.TOkneat.com, Inc.7.89x 796.30x $16.1M -$495.2K CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns KSI.TO or HEAL.CX?
has a net margin of -3.07% compared to kneat.com, Inc.'s net margin of --. kneat.com, Inc.'s return on equity of -2.02% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KSI.TOkneat.com, Inc.55.39% -$0.01 $96.2M HEAL.CX-- -- -- -
What do Analysts Say About KSI.TO or HEAL.CX?
kneat.com, Inc. has a consensus price target of $6.80, signalling upside risk potential of 37.1%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that kneat.com, Inc. has higher upside potential than , analysts believe kneat.com, Inc. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings KSI.TOkneat.com, Inc.2 0 0 HEAL.CX0 0 0 -
Is KSI.TO or HEAL.CX More Risky?
kneat.com, Inc. has a beta of 1.459, which suggesting that the stock is 45.948% more volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock KSI.TO or HEAL.CX?
kneat.com, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. kneat.com, Inc. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KSI.TO or HEAL.CX?
kneat.com, Inc. quarterly revenues are $16.1M, which are larger than quarterly revenues of --. kneat.com, Inc.'s net income of -$495.2K is higher than 's net income of --. Notably, kneat.com, Inc.'s price-to-earnings ratio is 796.30x while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for kneat.com, Inc. is 7.89x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KSI.TOkneat.com, Inc.7.89x 796.30x $16.1M -$495.2K HEAL.CX-- -- -- --
-
Which has Higher Returns KSI.TO or LOBE.CX?
Lobe Sciences Ltd. has a net margin of -3.07% compared to kneat.com, Inc.'s net margin of --. kneat.com, Inc.'s return on equity of -2.02% beat Lobe Sciences Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KSI.TOkneat.com, Inc.55.39% -$0.01 $96.2M LOBE.CXLobe Sciences Ltd.-- -$0.01 $5.9M -
What do Analysts Say About KSI.TO or LOBE.CX?
kneat.com, Inc. has a consensus price target of $6.80, signalling upside risk potential of 37.1%. On the other hand Lobe Sciences Ltd. has an analysts' consensus of -- which suggests that it could grow by 14192.33%. Given that Lobe Sciences Ltd. has higher upside potential than kneat.com, Inc., analysts believe Lobe Sciences Ltd. is more attractive than kneat.com, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KSI.TOkneat.com, Inc.2 0 0 LOBE.CXLobe Sciences Ltd.0 0 0 -
Is KSI.TO or LOBE.CX More Risky?
kneat.com, Inc. has a beta of 1.459, which suggesting that the stock is 45.948% more volatile than S&P 500. In comparison Lobe Sciences Ltd. has a beta of 0.215, suggesting its less volatile than the S&P 500 by 78.507%.
-
Which is a Better Dividend Stock KSI.TO or LOBE.CX?
kneat.com, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lobe Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. kneat.com, Inc. pays -- of its earnings as a dividend. Lobe Sciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KSI.TO or LOBE.CX?
kneat.com, Inc. quarterly revenues are $16.1M, which are larger than Lobe Sciences Ltd. quarterly revenues of --. kneat.com, Inc.'s net income of -$495.2K is higher than Lobe Sciences Ltd.'s net income of -$1.1M. Notably, kneat.com, Inc.'s price-to-earnings ratio is 796.30x while Lobe Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for kneat.com, Inc. is 7.89x versus -- for Lobe Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KSI.TOkneat.com, Inc.7.89x 796.30x $16.1M -$495.2K LOBE.CXLobe Sciences Ltd.-- -- -- -$1.1M
-
Which has Higher Returns KSI.TO or NSHS.CX?
NanoSphere Health Sciences, Inc. has a net margin of -3.07% compared to kneat.com, Inc.'s net margin of --. kneat.com, Inc.'s return on equity of -2.02% beat NanoSphere Health Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KSI.TOkneat.com, Inc.55.39% -$0.01 $96.2M NSHS.CXNanoSphere Health Sciences, Inc.-- -$0.00 -$1.8M -
What do Analysts Say About KSI.TO or NSHS.CX?
kneat.com, Inc. has a consensus price target of $6.80, signalling upside risk potential of 37.1%. On the other hand NanoSphere Health Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that kneat.com, Inc. has higher upside potential than NanoSphere Health Sciences, Inc., analysts believe kneat.com, Inc. is more attractive than NanoSphere Health Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KSI.TOkneat.com, Inc.2 0 0 NSHS.CXNanoSphere Health Sciences, Inc.0 0 0 -
Is KSI.TO or NSHS.CX More Risky?
kneat.com, Inc. has a beta of 1.459, which suggesting that the stock is 45.948% more volatile than S&P 500. In comparison NanoSphere Health Sciences, Inc. has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.292%.
-
Which is a Better Dividend Stock KSI.TO or NSHS.CX?
kneat.com, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoSphere Health Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. kneat.com, Inc. pays -- of its earnings as a dividend. NanoSphere Health Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KSI.TO or NSHS.CX?
kneat.com, Inc. quarterly revenues are $16.1M, which are larger than NanoSphere Health Sciences, Inc. quarterly revenues of --. kneat.com, Inc.'s net income of -$495.2K is lower than NanoSphere Health Sciences, Inc.'s net income of -$13.1K. Notably, kneat.com, Inc.'s price-to-earnings ratio is 796.30x while NanoSphere Health Sciences, Inc.'s PE ratio is 0.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for kneat.com, Inc. is 7.89x versus -- for NanoSphere Health Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KSI.TOkneat.com, Inc.7.89x 796.30x $16.1M -$495.2K NSHS.CXNanoSphere Health Sciences, Inc.-- 0.52x -- -$13.1K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 41.14% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 1.41% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 5.01% over the past day.
